Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM.

Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547.

2.

Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.

Roy HK, Turzhitsky V, Wali R, Radosevich AJ, Jovanovic B, Della'Zanna G, Umar A, Rubin DT, Goldberg MJ, Bianchi L, De La Cruz M, Bogojevic A, Helenowski IB, Rodriguez L, Chatterton R, Skripkauskas S, Page K, Weber CR, Huang X, Richmond E, Bergan RC, Backman V.

Gut. 2017 Feb;66(2):285-292. doi: 10.1136/gutjnl-2015-309996. Epub 2015 Oct 26.

3.

Genistein suppresses FLT4 and inhibits human colorectal cancer metastasis.

Xiao X, Liu Z, Wang R, Wang J, Zhang S, Cai X, Wu K, Bergan RC, Xu L, Fan D.

Oncotarget. 2015 Feb 20;6(5):3225-39.

4.

Diminished expression of h2-calponin in prostate cancer cells promotes cell proliferation, migration and the dependence of cell adhesion on substrate stiffness.

Moazzem Hossain M, Wang X, Bergan RC, Jin JP.

FEBS Open Bio. 2014 Jun 24;4:627-36. doi: 10.1016/j.fob.2014.06.003. eCollection 2014.

5.

Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.

Pavese JM, Ogden IM, Voll EA, Huang X, Xu L, Jovanovic B, Bergan RC.

PLoS One. 2014 Jul 14;9(7):e102289. doi: 10.1371/journal.pone.0102289. eCollection 2014.

6.

Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.

Pavese JM, Bergan RC.

Cancer Lett. 2014 Oct 1;352(2):179-86. doi: 10.1016/j.canlet.2014.06.012. Epub 2014 Jul 10.

7.

Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis.

Pavese JM, Krishna SN, Bergan RC.

Am J Clin Nutr. 2014 Jul;100 Suppl 1:431S-6S. doi: 10.3945/ajcn.113.071290. Epub 2014 May 28. Review.

8.

Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression.

Voll EA, Ogden IM, Pavese JM, Huang X, Xu L, Jovanovic BD, Bergan RC.

Oncotarget. 2014 May 15;5(9):2648-63.

9.

Circulating giant macrophages as a potential biomarker of solid tumors.

Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3514-9. doi: 10.1073/pnas.1320198111. Epub 2014 Feb 18.

10.

Therapeutic modulation of prostate cancer metastasis.

Krishna SN, Bergan RC.

Future Med Chem. 2014 Feb;6(2):223-39. doi: 10.4155/fmc.13.201. Review.

PMID:
24467245
11.

A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4.

Krishna SN, Luan CH, Mishra RK, Xu L, Scheidt KA, Anderson WF, Bergan RC.

PLoS One. 2013 Dec 5;8(12):e81504. doi: 10.1371/journal.pone.0081504. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/5edeb1de-b76c-4fd9-a3f6-0f1cf45e3905.

12.

An orthotopic murine model of human prostate cancer metastasis.

Pavese J, Ogden IM, Bergan RC.

J Vis Exp. 2013 Sep 18;(79):e50873. doi: 10.3791/50873.

13.

Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors.

Breen MJ, Moran DM, Liu W, Huang X, Vary CP, Bergan RC.

PLoS One. 2013 Aug 13;8(8):e72407. doi: 10.1371/journal.pone.0072407. eCollection 2013.

14.

A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia.

Wong SJ, Campbell B, Massey B, Lynch DP, Cohen EEW, Blair E, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi V, Bergan RC, Szabo E.

Oral Oncol. 2013 Sep;49(9):970-976. doi: 10.1016/j.oraloncology.2013.05.011. Epub 2013 Jul 8.

15.

Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.

Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J.

Cancer Res. 2013 Jun 15;73(12):3725-36. doi: 10.1158/0008-5472.CAN-12-3468. Epub 2013 Mar 28.

16.

Crystal structure of a type II dehydroquinate dehydratase-like protein from Bifidobacterium longum.

Light SH, Krishna SN, Bergan RC, Lavie A, Anderson WF.

J Struct Funct Genomics. 2013 Mar;14(1):25-30. doi: 10.1007/s10969-013-9149-7. Epub 2013 Mar 29.

17.

Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial.

Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, Heinz R, Zalles CM, Helenowski IB, Jovanovic BD, Franke AA, Bosland MC, Wang J, Hansen NM, Bethke KP, Dew A, Coomes M, Bergan RC.

Cancer Prev Res (Phila). 2012 Feb;5(2):309-19. doi: 10.1158/1940-6207.CAPR-11-0251.

18.

The Ninth Annual American Association of cancer research international conference on frontiers in cancer prevention research.

Xu L, Wang SS, Healey MA, Faupel-Badger JM, Wilken JA, Battaglia T, Szabo E, Mao JT, Bergan RC.

Cancer Prev Res (Phila). 2011 Apr;4(4):616-21. doi: 10.1158/1940-6207.CAPR-11-0018.

19.

Endoglin regulates cancer-stromal cell interactions in prostate tumors.

Romero D, O'Neill C, Terzic A, Contois L, Young K, Conley BA, Bergan RC, Brooks PC, Vary CP.

Cancer Res. 2011 May 15;71(10):3482-93. doi: 10.1158/0008-5472.CAN-10-2665. Epub 2011 Mar 28. Erratum in: Cancer Res. 2012 Feb 15;72(4):1037.

20.

Concise syntheses of the abyssinones and discovery of new inhibitors of prostate cancer and MMP-2 expression.

Farmer RL, Biddle MM, Nibbs AE, Huang X, Bergan RC, Scheidt KA.

ACS Med Chem Lett. 2010 Nov 11;1(8):400-405.

21.

Endoglin suppresses human prostate cancer metastasis.

Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, Craft CS, Romero D, Vary CP, Bergan RC.

Clin Exp Metastasis. 2011 Jan;28(1):39-53. doi: 10.1007/s10585-010-9356-6. Epub 2010 Oct 28.

22.

Inhibition of cancer cell invasion and metastasis by genistein.

Pavese JM, Farmer RL, Bergan RC.

Cancer Metastasis Rev. 2010 Sep;29(3):465-82. doi: 10.1007/s10555-010-9238-z. Review.

23.

Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration.

Romero D, Terzic A, Conley BA, Craft CS, Jovanovic B, Bergan RC, Vary CP.

Carcinogenesis. 2010 Mar;31(3):359-66. doi: 10.1093/carcin/bgp217. Epub 2009 Sep 7.

24.

MEK4 function, genistein treatment, and invasion of human prostate cancer cells.

Xu L, Ding Y, Catalona WJ, Yang XJ, Anderson WF, Jovanovic B, Wellman K, Killmer J, Huang X, Scheidt KA, Montgomery RB, Bergan RC.

J Natl Cancer Inst. 2009 Aug 19;101(16):1141-55. doi: 10.1093/jnci/djp227. Epub 2009 Jul 28.

25.

Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images.

Paunesku T, Ke T, Dharmakumar R, Mascheri N, Wu A, Lai B, Vogt S, Maser J, Thurn K, Szolc-Kowalska B, Larson A, Bergan RC, Omary R, Li D, Lu ZR, Woloschak GE.

Nanomedicine. 2008 Sep;4(3):201-7. doi: 10.1016/j.nano.2008.04.004. Epub 2008 Jun 24.

26.

Dietary genistein inhibits metastasis of human prostate cancer in mice.

Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, Helenowski I, Pelling JC, Bergan RC.

Cancer Res. 2008 Mar 15;68(6):2024-32. doi: 10.1158/0008-5472.CAN-07-1246.

27.

Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells.

Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC.

Mol Carcinog. 2008 Sep;47(9):686-700. doi: 10.1002/mc.20421.

PMID:
18240292
28.

The methodology used to measure differential gene expression affects the outcome.

Ding Y, Xu L, Jovanovic BD, Helenowski IB, Kelly DL, Catalona WJ, Yang XJ, Pins M, Bergan RC.

J Biomol Tech. 2007 Dec;18(5):321-30.

29.

Associations of serum carotenoid levels with serum insulin-like growth factor-i and insulin-like growth factor binding protein-3 levels in black men and white men.

Kim YL, Jacobs DR Jr, Gross MD, Bergan RC, Gann PH, Liu K, Gapstur SM.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2781-3. No abstract available.

30.

Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells.

Craft CS, Xu L, Romero D, Vary CP, Bergan RC.

Mol Pharmacol. 2008 Jan;73(1):235-42. Epub 2007 Oct 19.

31.

Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.

Craft CS, Romero D, Vary CP, Bergan RC.

Oncogene. 2007 Nov 8;26(51):7240-50. Epub 2007 May 14.

32.

Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.

Ding Y, Xu L, Chen S, Jovanovic BD, Helenowski IB, Kelly DL, Catalona WJ, Yang XJ, Pins M, Ananthanarayanan V, Bergan RC.

Prostate Cancer Prostatic Dis. 2006;9(4):379-91. Epub 2006 Jun 20.

PMID:
16786039
34.

Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.

Eklund J, Kozloff M, Vlamakis J, Starr A, Mariott M, Gallot L, Jovanovic B, Schilder L, Robin E, Pins M, Bergan RC.

Cancer. 2006 Jun 1;106(11):2459-65.

36.

Renal medullary carcinoma and ABL gene amplification.

Simpson L, He X, Pins M, Huang X, Campbell SC, Yang XJ, Perlman EJ, Bergan RC.

J Urol. 2005 Jun;173(6):1883-8.

PMID:
15879768
37.

Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells.

Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC, Bergan RC.

Cancer Res. 2005 Apr 15;65(8):3470-8.

38.

Safety and efficacy of weekly oral oltipraz in chronic smokers.

Kelley MJ, Glaser EM, Herndon JE 2nd, Becker F, Bhagat R, Zhang YJ, Santella RM, Carmella SG, Hecht SS, Gallot L, Schilder L, Crowell JA, Perloff M, Folz RJ, Bergan RC.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):892-9.

39.

Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer.

Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M, Jovanovic BD, Shapiro A, Hernandez L, Goetz A, Llorens V, Lieberman R, Crowell JA, Poisson BA, Bergan RC.

Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1213-21.

40.

p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion.

Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC.

Oncogene. 2003 Jul 31;22(31):4841-50.

PMID:
12894225
41.

An analysis of gene array data related to cell adhesion and prostate cancer.

Jovanovic BD, Huang S, Liu Y, Naguib KN, Bergan RC.

Cancer Treat Res. 2002;113:91-111. Review. No abstract available.

PMID:
12613352
42.

Some aspects of analysis of gene array data.

Jovanovic BD, Bergan RC, Kibbe WA.

Cancer Treat Res. 2002;113:71-89. Review. No abstract available.

PMID:
12613351
43.

Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells.

Liu YQ, Kyle E, Patel S, Housseau F, Hakim F, Lieberman R, Pins M, Blagosklonny MV, Bergan RC.

Prostate Cancer Prostatic Dis. 2001;4(2):81-91.

44.

Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion.

Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC.

Oncogene. 2002 Nov 28;21(54):8272-81.

45.

A simple analysis of gene expression and variability in gene arrays based on repeated observations.

Jovanovic BD, Huang S, Liu Y, Naguib KN, Bergan RC.

Am J Pharmacogenomics. 2001;1(2):145-52.

PMID:
12174675
46.

Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation.

Liu Y, Kyle E, Lieberman R, Crowell J, Kellof G, Bergan RC.

Clin Exp Metastasis. 2000;18(3):203-12.

PMID:
11315093
47.

Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer.

Bergan RC, Waggle DH, Carter SK, Horak I, Slichenmyer W, Meyers M.

Urology. 2001 Apr;57(4 Suppl 1):77-80.

PMID:
11295600
48.

A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.

Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV.

Clin Cancer Res. 1999 Sep;5(9):2366-73.

49.
50.

Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity.

Schwartz GN, Liu YQ, Tisdale J, Walshe K, Fowler D, Gress R, Bergan RC.

Antisense Nucleic Acid Drug Dev. 1998 Aug;8(4):329-39.

PMID:
9743470

Supplemental Content

Loading ...
Support Center